IL23A and psoriasis vulgaris: Risankizumab, a monoclonal antibody targeting interleukin-23A (IL-23A), is primarily indicated for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis (Gordon et al., 2018).